secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2024-06-17T23:59:59+00:00
Accession:  0001193125-24-162715
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics director Ujwala Mahatme resigns; annual meeting elects all eight nominees
--------------------------------------------------------------------------------

- Director Ujwala Mahatme resigned effective June 12, 2024, to focus on professional commitments; no disagreement with company.
- At June 14 annual meeting, all eight director nominees elected with large majorities (e.g., Robert W. Duggan received 620.6M votes).
- Stockholders ratified PwC as independent auditor for FY 2024 with 639.3M votes for and 39.8K against.
- Non-binding advisory vote on executive compensation passed with 604.2M for, 15.9M against, and 18.9M broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000119312524162715/0001193125-24-162715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000119312524162715/d786440d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-162715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer